
Opinion|Videos|January 15, 2025
Adverse Event Management and Emerging Therapies in Ovarian Cancer: PARPi Challenges and the Role of ADCs
Author(s)Thomas J. Herzog, MD, John Chan, MD
Panelists discuss the most common adverse events associated with PARP inhibitor (PARPi) therapy in ovarian cancer and strategies for mitigating or managing these adverse effects. They also review recent data on antibody-drug conjugates (ADCs) in ovarian cancer, including the evolving role of mirvetuximab soravtansine in the FORWARD II trial, and other ADCs such as luveltamab tazevibulin and rinatabart sesutecan, highlighting promising findings from studies presented at ESMO 2024. The session concludes with a discussion on future perspectives in ovarian cancer treatment, offering insights into emerging therapies and the evolving landscape.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Dr Chan to Dr Herzog: What adverse events are most seen with PARPi therapy, and how do you mitigate or manage these?
- Dr Herzog: Briefly comment on recent data surrounding ADCs in ovarian cancer and discuss the evolving role of these agents in the treatment landscape.
- Dr Herzog to address: Mirvetuximab soravtansine (anti-FR)
- FORWARD II (
Gynecol Oncol. 2024 MIRASOL) (N Engl J Med. 2023 ;ASCO 2024 abstract 5582 ) - Dr Chan to address: Luveltamab tazevibulin (anti-FR), Rinatabart sesutecan (Rina-S)
- Rinatabart sesutecan (Rina-S) -
Lee EK, et al. ESMO 2024. Abs 719MO - STRO-002-GM1 (
Pothuri, et al. ESMO 2023. Abstract 741MO )
- All faculty: Please share future perspectives and closing thoughts on the treatment of ovarian cancer.
Advertisement
Related to this article

The CHMP backed sintilimab plus chemotherapy in NSCLC; the FDA issued a complete response letter for the regimen in 2022.

The FDA removed the PCNSL limitation of use from the liso-cel label in LBCL, making it the second CAR T-cell therapy with this update.

Quality Improvement and EGFR-Mutant Lung Cancer Survivorship Research Help Shape Fellowship Training
Christine Ann Garcia, MD, MPH, discusses error review in fellowship training, survivorship in EGFR+ lung cancer, and nontraditional career paths.

Sanjiv Gangaram-Panday, MD, PhD, discusses 5-year SANO outcomes, distant dissemination, and next steps for active surveillance in esophageal cancer.

Alissa Cooper, MD, reviews new data for established and emerging antibody-drug conjugate targets in non–small cell lung cancer and argues that payload innovation and better patient selection are the field's greatest needs.

The FDA accepted an sNDA for selinexor plus ruxolitinib in myelofibrosis, with a target action date of June 28, 2027.

The FDA has approved neladalkib for previously treated, ALK-positive, locally advanced or metastatic non-small cell lung cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Removes Limitations of Use for Liso-Cel in Primary Central Nervous System Lymphoma
2
FDA Accepts sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis
3
Beyond the Target: Payloads, Therapeutic Windows, and Biomarkers Shape the Next Wave of ADCs in NSCLC
4
Sintilimab Receives Positive CHMP Opinion for First-Line Nonsquamous NSCLC
5

